BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 11605085)

  • 1. Activation of 5-HT(2C) receptors reduces the locomotor and rewarding effects of nicotine.
    Grottick AJ; Corrigall WA; Higgins GA
    Psychopharmacology (Berl); 2001 Sep; 157(3):292-8. PubMed ID: 11605085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple 5-HT receptors are involved in the effects of acute MDMA treatment: studies on locomotor activity and responding for conditioned reinforcement.
    Fletcher PJ; Korth KM; Robinson SR; Baker GB
    Psychopharmacology (Berl); 2002 Jul; 162(3):282-91. PubMed ID: 12122486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of 5-HT2C receptor activation by WAY 161503 on nicotine-induced place conditioning and locomotor activity in rats.
    Hayes DJ; Mosher TM; Greenshaw AJ
    Behav Brain Res; 2009 Feb; 197(2):323-30. PubMed ID: 18805442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies to investigate the role of 5-HT(2C) receptors on cocaine- and food-maintained behavior.
    Grottick AJ; Fletcher PJ; Higgins GA
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1183-91. PubMed ID: 11082456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective stimulation of serotonin2c receptors blocks the enhancement of striatal and accumbal dopamine release induced by nicotine administration.
    Di Matteo V; Pierucci M; Esposito E
    J Neurochem; 2004 Apr; 89(2):418-29. PubMed ID: 15056285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing the effects of 5-HT(2C) receptor ligands on motor activity and feeding behaviour in 5-HT(2C) receptor knockout mice.
    Fletcher PJ; Tampakeras M; Sinyard J; Slassi A; Isaac M; Higgins GA
    Neuropharmacology; 2009 Sep; 57(3):259-67. PubMed ID: 19501602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study.
    Di Giovanni G; Di Matteo V; Di Mascio M; Esposito E
    Synapse; 2000 Jan; 35(1):53-61. PubMed ID: 10579808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulation of serotonin2C receptors blocks the hyperactivation of midbrain dopamine neurons induced by nicotine administration.
    Pierucci M; Di Matteo V; Esposito E
    J Pharmacol Exp Ther; 2004 Apr; 309(1):109-18. PubMed ID: 14722316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo evidence that constitutive activity of serotonin2C receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist.
    Leggio GM; Cathala A; Neny M; Rouge-Pont F; Drago F; Piazza PV; Spampinato U
    J Neurochem; 2009 Oct; 111(2):614-23. PubMed ID: 19702657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of serotonin (5-HT)2 receptor ligands on depression-like behavior during nicotine withdrawal.
    Zaniewska M; McCreary AC; Wydra K; Filip M
    Neuropharmacology; 2010 Jun; 58(7):1140-6. PubMed ID: 20153341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ejaculatory response induced by a 5-HT2 receptor agonist m-CPP in rats: differential roles of 5-HT2 receptor subtypes.
    Yonezawa A; Yoshizumi M; Ebiko M; Ise SN; Watanabe C; Mizoguchi H; Kimura Y; Sakurada S
    Pharmacol Biochem Behav; 2008 Feb; 88(4):367-73. PubMed ID: 17936345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Injection of the 5-HT2C receptor agonist Ro60-0175 into the ventral tegmental area reduces cocaine-induced locomotor activity and cocaine self-administration.
    Fletcher PJ; Chintoh AF; Sinyard J; Higgins GA
    Neuropsychopharmacology; 2004 Feb; 29(2):308-18. PubMed ID: 14666118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of serotonin (5-HT)2 receptor-targeting ligands and nicotine: locomotor activity studies in rats.
    Zaniewska M; McCreary AC; Filip M
    Synapse; 2009 Aug; 63(8):653-61. PubMed ID: 19347958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of serotonin (5-HT)2 receptor-targeting ligands on locomotor responses to nicotine-repeated treatment.
    Zaniewska M; McCreary AC; Wydra K; Filip M
    Synapse; 2010 Jul; 64(7):511-9. PubMed ID: 20196140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of 5-HT2C receptor ligands on place conditioning and locomotor activity in rats.
    Mosher T; Hayes D; Greenshaw A
    Eur J Pharmacol; 2005 May; 515(1-3):107-16. PubMed ID: 15896731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors.
    Cryan JF; Lucki I
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1120-6. PubMed ID: 11082448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuation of nicotine's discriminative stimulus effects in rats and its locomotor activity effects in mice by serotonergic 5-HT2A/2C receptor agonists.
    Batman AM; Munzar P; Beardsley PM
    Psychopharmacology (Berl); 2005 May; 179(2):393-401. PubMed ID: 15565434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and pharmacological evidence that 5-HT2C receptor activation, but not inhibition, affects motivation to feed under a progressive ratio schedule of reinforcement.
    Fletcher PJ; Sinyard J; Higgins GA
    Pharmacol Biochem Behav; 2010 Nov; 97(1):170-8. PubMed ID: 20624416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective activation of 5-HT(2C) receptors stimulates GABA-ergic function in the rat substantia nigra pars reticulata: a combined in vivo electrophysiological and neurochemical study.
    Invernizzi RW; Pierucci M; Calcagno E; Di Giovanni G; Di Matteo V; Benigno A; Esposito E
    Neuroscience; 2007 Feb; 144(4):1523-35. PubMed ID: 17161544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.
    Marquis KL; Sabb AL; Logue SF; Brennan JA; Piesla MJ; Comery TA; Grauer SM; Ashby CR; Nguyen HQ; Dawson LA; Barrett JE; Stack G; Meltzer HY; Harrison BL; Rosenzweig-Lipson S
    J Pharmacol Exp Ther; 2007 Jan; 320(1):486-96. PubMed ID: 17038512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.